Virgin Group II (NYSE:VGII) announced that its shareholders have voted to approve its combination with sustainable home products-maker Grove in a special meeting held earlier today.
Today’s press release was short on details and did not disclose redemption numbers, but VGII traded below its trust value throughout its redemption deadline June 10, and closed today at $5.96.
The SPAC recently added a $50 million backstop to its combination with Grove Collective and agreed to waive its minimum cash condition in exchange for the new agreements. The new money was in the form of two tranches with Corvina Holdings investing $27.5 million into a PIPE effectively at $10 per share at close. It also further agreed to purchase $22.5 million in shares, but may redeem these proportionate to the amount that the deal’s closing cash exceeds that amount.
The parties expect to close the business combination on June 16, 2022, subject to the satisfaction of customary closing conditions. VGII will change its name to “Grove Collaborative Holdings, Inc.” and its shares and warrants are expected to begin trading on the New York Stock Exchange under the ticker symbols “GROV” and “GROV WS”, respectively on June 17, 2022.
VGII initially announced the $1.5 billion combination with Grove on December 8. San Francisco-based Grove makes sustainable home and beauty products sold primarily though its native ecommerce platform.
More than 91% of the votes cast at today’s special meeting were in favor of the business combination. VGII shareholders also voted overwhelmingly to approve all other proposals presented on the ballot.
ADVISORS
- Morgan Stanley & Co. LLC is acting as exclusive financial advisor to Grove
- Credit Suisse Securities (USA) LLC is acting as financial advisor and capital markets advisor to VGII.
- Sidley Austin LLP is acting as the legal advisor to Grove
- Davis Polk & Wardwell LLP is acting as the legal advisor to VGII.
- Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC are serving as co-placement agents to VGII with respect to the portion of the PIPE financing raised from qualified institutional buyers and institutional accredited investors.
- Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC are not acting as agents or participating in any role with respect to, and will not earn any fees from, the portion of the PIPE financing raised from individual investors.
- Credit Suisse Securities (USA) LLC previously acted as sole book-running manager for VGII’s IPO.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...